CybinInc @CybinInc Twitter profile

Last Seen Profiles

@LAbwzryq76283

@AI_sara86

@AnnaChodor84252

@stw_pdg

@SonyKomanduri

@BeeismRblx

@umitwt

@Dr_Hell_2011

@ezhoff6

@Fronkensteen

@jandakembangstw

@JiVlk7

@abijeon96

@AnnaChodor84252

@24HorasPuebla

@dmz9f4r2ubii0p

@alta1r

@mononogatari_pr

@Clumsterscore

@BALLSBEINGKICK

@giantess947

@bokeplokalmalam

@ynglive

@whostyoma

@KerkvlietM56655

@UnitedShoes

@sweetbulba

@ArobaseYD

@bokeplokalmalam

@evgenyrodionov

@edgardelgadoii

@TeresaG27044374

@lakithianicole

@checrygin

@Keisinger

@2fast2furios

CybinInc

@CybinInc

1 year

BREAKING: We are excited to announce unprecedented positive Phase 2 interim efficacy data for CYB003 in major depressive disorder. The results showed: -A rapid and robust reduction in depression symptoms three weeks after a single 12mg dose of CYB003, with a clinically

8

31

119

CybinInc

@CybinInc

11 months

#BREAKING Positive Topline Data: In Cybin's Phase 2 study of CYB003 in major depressive disorder, 79% of patients were in remission from depression after just two doses (12mg) These results showed rapid and large improvements in symptoms of depression observed after single

11

36

111

CybinInc

@CybinInc

2 years

Cybin announces approval of first-in-human dosing of CYB004, marking the first-ever trial to evaluate deuterated DMT in humans. Read more: $CYBN #mentalhealth #clinicaltrials #cybin

1

20

102

CybinInc

@CybinInc

7 months

#BREAKING CYB003, Cybin's proprietary deuterated psilocybin analogue for the adjunctive treatment of Major Depressive Disorder (MDD), has received Breakthrough Therapy Designation ( #BTD ) from the U.S. Food and Drug Administration ( #FDA ). BTD provides an expedited review

9

25

98

CybinInc

@CybinInc

2 years

Psilocybin Company of the Year. "We are honored to be recognized as the leading innovator of psilocybin therapies. Improving the patient experience and optimizing patient access is at the center of our mission to revolutionize mental healthcare." -CEO Doug Drysdale $CYBN

4

18

89

CybinInc

@CybinInc

8 months

Cybin is pleased to announce the grant of two additional patents in Japan, the 3rd largest pharmaceutical market globally, in support of our deuterated dimethyltryptamine ( #DMT ) program. Learn more: $CYBN #MentalHealthInnovation #Biotech #Anxiety #IP

5

22

89

CybinInc

@CybinInc

7 months

#Cybin has initiated a Phase 2 proof-of-concept study for #CYB004 , our proprietary deuterated DMT molecule for the treatment of Generalized Anxiety Disorder #GAD . Learn more: ↩️ #Anxiety #Psychedelics #MentalHealthInnovation #Biotechnology #IND

8

38

86

CybinInc

@CybinInc

11 months

"8 out of 10 patients were no longer depressed at 6 weeks after two doses of CYB003 12mg" — Cybin Chief Medical Officer @dramirinamdar at the R&D Briefing on topline data from our Phase 2 study of CYB003 in MDD. Watch the full briefing: 📺

3

20

81

CybinInc

@CybinInc

9 months

#BREAKING : The FDA has cleared Cybin's investigational new drug application for CYB004 — our proprietary deuterated DMT molecule — allowing us to proceed with a Phase 2a GAD study of CYB004 in Q1 2024. "We have gathered important insights on dosing and preliminary efficacy

9

25

82

CybinInc

@CybinInc

10 months

"I see these results as the biggest breakthrough in psychiatric pharmacology in the last 40 years — 8 out of 10 patients were no longer depressed at 6 weeks after two doses of CYB003 12mg." Watch Cybin's R&D Briefing on phase 2 data from CYB003 in MDD: 📺

3

21

76

CybinInc

@CybinInc

9 months

#BREAKING : Cybin announces positive data from Phase 1 studies of #CYB004 and #SPL028 . Results demonstrated pharmacokinetic (PK) and pharmacodynamic (PD) profiles with the potential to bridge data across these molecules, with both demonstrating concentrations in the effective

4

18

70

CybinInc

@CybinInc

7 months

#CYB003 , Cybin's proprietary deuterated psilocybin analog in development for the adjunctive treatment of #MajorDepressiveDisorder , demonstrated robust and sustained improvement in depression symptoms at four months — with 75% of patients in remission from depression after just

17

20

62

CybinInc

@CybinInc

4 years

Why Psychedelic Delivery Mechanisms Matter - CannabisFN @CannabisFN

1

14

63

CybinInc

@CybinInc

3 years

#BREAKING The FDA has authorized a phase 2 clinical trial evaluating psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress. Learn more: $CYBN #psychedelics #psychedelictherapy

1

19

64

CybinInc

@CybinInc

3 years

At Cybin, our team is on a mission to revolutionize mental healthcare. Meet the minds behind the mission and follow our journey to create safe and effective psychedelic treatments. #mentalhealth $CLXPF $CYBN

4

21

59

CybinInc

@CybinInc

11 months

#BREAKING Cybin shares topline data from its Phase 2 study of CYB003 in major depressive disorder at NYC R&D Briefing. Watch: 📺 Rapid and large improvements in symptoms of depression were observed after single doses of CYB003, with an incremental

4

11

63

CybinInc

@CybinInc

3 years

Cybin announces conditional listing approval from NYSE American. Learn more:

3

8

62

CybinInc

@CybinInc

3 years

Today, Cybin becomes the first psychedelic biotech company to trade on the @NYSE American! Join us in celebrating this milestone and follow our journey as we continue our mission to revolutionize mental healthcare. NYSE: $CYBN

3

15

60

CybinInc

@CybinInc

3 years

Cybin will commence trading on the @NYSE tomorrow, August 5th. NYSE: $CYBN

6

17

57

CybinInc

@CybinInc

1 year

Cybin is pleased to announce the completion of dosing in its Phase 2 study evaluating CYB003 for the treatment of major depressive disorder, with no serious adverse events observed in the final cohort. CYB003 is Cybin’s proprietary deuterated psilocybin analog, with the

7

19

58

CybinInc

@CybinInc

3 months

#Cybin has evolved into a mature, late-stage biotechnology company —rapidly achieving milestones towards our goal of revolutionizing mental healthcare. Learn more about our pipeline of next-generation treatment options: #MentalHealth #Biotechnology

3

12

63

CybinInc

@CybinInc

6 months

#CYB003 , Cybin's deuterated psilocybin analog, was developed to address the treatment gap in #depression — the leading cause of disability due to mental illness, affecting over 300 million people worldwide. Over 43 million Americans take antidepressants and over 70% of these

7

21

56

CybinInc

@CybinInc

1 year

Cybin is at the forefront of psychedelic therapeutics but what exactly are we creating? What sets us apart is that we use deuteration to make psychedelic molecules stronger and more effective, innovating forms of psilocybin, DMT and phenethylamines to improve their therapeutic

5

13

56

CybinInc

@CybinInc

10 months

"Cybin is advancing the scientific discovery of #psychedelics , uncovering their medicinal properties, progressing #clinicalresearch , & raising public awareness of — and #investor interest in — the future of mental health therapeutics." — Cybin CEO Doug Drysdale @insidepharma at

3

12

57

CybinInc

@CybinInc

1 year

Cybin has completed enrollment in the final cohort of its Phase 2 study of #CYB003 — a proprietary deuterated psilocybin analog — in major depressive disorder. “The completion of enrollment and near-completion of dosing in our Phase 2 CYB003 study is a significant milestone

10

18

52

CybinInc

@CybinInc

3 years

#BREAKING Cybin receives final approval to commence trading on the @NYSE American on or about August 5th $CYBN

1

14

56

CybinInc

@CybinInc

7 months

The U.S. #FDA has granted #BTD : Breakthrough Therapy Designation to Cybin's #CYB003 for adjunctive psychedelic-based therapy in the treatment of Major Depressive Disorder. Learn more: Watch Webcast ] & Read Press Release ↩️

4

10

57

CybinInc

@CybinInc

3 years

#BREAKING The USPTO has granted a patent to Cybin for its proprietary deuterated DMT compound CYB004. Cybin plans to initiate the pilot study for CYB004 in Q3 CY2022. Learn more: $CYBN #psychedelics #mentalhealth

3

12

53

CybinInc

@CybinInc

1 year

Some exciting highlights from our unprecedented positive Phase 2 interim efficacy data for CYB003. $CYBN #ChangingMinds #researchanddevelopment #cybin #psychedelicresearch #clinicalresearch #mentalhealthresearch #CybinInc #DrugDevelopment #Biotech #MentalHealth

1

13

56

CybinInc

@CybinInc

7 months

Cybin's #CYB003 has been granted Breakthrough Therapy Designation #BTD by the #FDA , bringing us closer to the goal of revolutionizing mental healthcare. Learn more: Webcast - Press Release - Visit -

0

19

55

CybinInc

@CybinInc

2 years

#InTheNews : The Biden Administration plans for legal psychedelic therapies within 2 years. A letter from the Health and Human Services Department discloses the anticipated FDA approval of MDMA and psilocybin treatments.

Biden Administration Plans for Legal Psychedelic Therapies Within Two Years

A letter from the Health and Human Services Department discloses the anticipated FDA approval of MDMA and psilocybin treatments.

theintercept.com

0

12

58

CybinInc

@CybinInc

10 months

This Christmas, let's embrace hope and healing. Cybinauts wish everyone a joyful season filled with peace and mental wellness. $CYBN #merrychristmas #christmas #Hope #Healing #MentalHealth #ChangingMinds #researchanddevelopment #cybin #psychedelicresearch #clinicalresearch

5

6

56

CybinInc

@CybinInc

8 months

#Cybin has built the world's largest psychedelic IP portfolio, with over 50 granted patents and 170 pending applications. Join our mission to revolutionize mental health care. #NYSE : CYBN | #NEO : CYBN Learn more: ↩

3

13

56

CybinInc

@CybinInc

1 year

Cybin is pleased to share that its Phase 2 trial evaluating CYB003 has completed dosing in Cohort 5 with no serious adverse events — a significant milestone towards realizing CYB003 as a differentiated and rapid-acting therapeutic option for people with major depressive disorder.

1

14

55

CybinInc

@CybinInc

11 months

“Securing robust patent protection for our proprietary products is a top priority, and we are pleased to announce this additional U.S. patent supporting our CYB003 program,” said Cybin CEO @insidepharma . "Last week, we shared positive Phase 2 topline safety and efficacy data

0

14

55

CybinInc

@CybinInc

1 year

Cybin is pleased to announce an agreement with @Fluencetraining — a leading continuing education organization in psychedelic therapy — to support the streamlining and scaling of Cybin’s EMBARK facilitator training program in preparation for a multi-site, global Phase 3 trial of

3

15

53

CybinInc

@CybinInc

6 months

We are excited to announce that Cybin's work on novel phenethylamine 5-HT receptor agonists has been published in #JMedChem Congratulations to our scientific leadership team on this accomplishment and important work highlighting Cybin's expanding scope of development and

3

17

54

CybinInc

@CybinInc

9 months

Anxiety disorders are the most common mental health conditions globally. Read the following guide to Cybin's research in proprietary dimethylryptamine (DMT) formulations to treat Generalized Anxiety Disorder (GAD) and bring enhanced treatment options for patients around the

9

17

52

CybinInc

@CybinInc

3 months

Learn more about #CYB004 : Cybin's Phase 2 proprietary deuterated dimethyltryptamine #DMT program for the treatment of Generalized Anxiety Disorder #GAD : ↩️ #MentalHealth #Biotechnology

1

17

55

CybinInc

@CybinInc

16 days

"This is the biggest breakthrough in psychiatry in 40 years." Yesterday, @insidepharma made a guest appearance on @drdrew on @FoxBusiness to talk about the breakthrough innovations Cybin is developing to revolutionize the treatment of mental health. Watch:

2

19

54

CybinInc

@CybinInc

5 months

"We've been treating #depression wrong for the past 40 years, assuming it was caused by abnormalities in neurotransmitter levels — but there are so many patients that don't respond. What we know now is that depression is likely a function of brain connectivity. #Cybin 's modified

0

19

52

CybinInc

@CybinInc

1 year

We are excited to announce the grant of two new U.S. patents protecting Cybin's deuterated DMT program, adding to the most robust intellectual property portfolio in the psychedelic drug development sector. “Following Cybin’s recent acquisition of @SmallPharma , our development

4

12

51

CybinInc

@CybinInc

1 year

Cybin has an exciting journey ahead with multiple key data readouts and clinical milestones expected in the coming months and next year across the pipeline. We look forward to sharing: - Complete Phase 2 CYB003 efficacy and safety data in MDD in Q4 2023 - Phase 1 data for

3

10

52

CybinInc

@CybinInc

1 year

We are pleased to announce the grant of a European Patent protecting Cybin's deuterated psilocybin analog and deuterated DMT programs. This patent, in addition to the two recently announced U.S. patents, further strengthens Cybin's growing IP portfolio. “Maintaining a secure

7

14

50

CybinInc

@CybinInc

7 months

Cybin is pleased to announce the initiation of a Phase 2 proof-of-concept study of #CYB004 , our proprietary #DMT molecule in development for the treatment of Generalized Anxiety Disorder #GAD . Learn more:

3

17

52

CybinInc

@CybinInc

2 years

Cybin is pleased to announce that the first two participants have been dosed in our Phase 1/2a trial evaluating CYB003 for the treatment of MDD. This clinical milestone marks the initiation of the first-ever novel psilocybin analog to enter clinical development.

4

10

49

CybinInc

@CybinInc

2 years

#BREAKING Cybin has received IRB approval to begin the first-in-human Phase 1/2a clinical trial evaluating CYB003 for the treatment of major depressive disorder. Learn more about the clinical trial here:

6

11

47

CybinInc

@CybinInc

10 months

Cybin recently released unprecedented positive Phase 2 data for CYB003 in Major Depressive Disorder. But what should the public make of the results and what are the implications for the treatment landscape for depression? Read our guide to the results below and watch our R&D

6

11

51

CybinInc

@CybinInc

1 year

Cybin commends @SmallPharma on its positive topline data from its Phase 1b study of SPL026 (DMT). This data showed that 4 weeks after treatment with SPL026, 92% of patients on SSRIs achieved remission from depression, and all patients on SSRIs responded to SPL026. “With our

0

15

49

CybinInc

@CybinInc

11 months

This Thursday, November 30 at 10am ET, Cybin will host an R&D Briefing where we will release topline Phase 2 efficacy data for CYB003 in Major Depressive Disorder, followed by a panel discussion with key opinion leaders on data and study designs, the current treatment landscape

2

11

47

CybinInc

@CybinInc

23 days

"Our results are unlike anything else we've ever seen in depression ever. Certainly, the best data that we've ever seen, both in the psychedelic sector and beyond as well. And in the next few weeks here, we expect to have 12-month follow-up data, and it'll be interesting." —

1

16

50

CybinInc

@CybinInc

10 months

#SSRIs have dose-limiting adverse effects & require daily, long-term use. 2/3 patients failing to remit with initial therapies. For #CYB003 , 8/10 patients were no longer depressed at 6 weeks after only two 12mg doses, with only mild to moderate self-limiting adverse effects.

6

16

47

CybinInc

@CybinInc

9 months

Did you know that #anxiety disorders are the most prevalent mental health disorders globally, contributing to over 28 million years of life lost to early death or living with disease or disability? Learn more about our work on #CYB004 #DMT as a next-generation treatment option

6

16

48

CybinInc

@CybinInc

7 months

Cybin has a concluded a positive End-of-Phase 2 meeting with the U.S. #FDA for #CYB003 , our deuterated psilocybin analogue for the adjunctive treatment of Major Depressive Disorder. “We are very pleased with the results of our End-of-Phase 2 meeting. Having aligned on key

9

14

47

CybinInc

@CybinInc

10 months

#Cybinauts are ringing in the New Year with a commitment to mental wellness and new beginnings. May 2024 bring you peace, health, and happiness. $CYBN #happynewyears2024 #newyear #mentalhealthawareness #ChangingMinds #researchanddevelopment #cybin #psychedelicresearch

8

48

CybinInc

@CybinInc

2 years

#BREAKING Cybin announces promising results from our sponsored @KernelCo feasibility study measuring psychedelic effects on the brain. Read the key findings from the feasibility study: $CYBN #psychedelic #kernel

2

12

44

CybinInc

@CybinInc

2 years

#BREAKING Cybin Receives FDA IND Clearance for CYB003's clinical trial. -CYB003 is the first novel psilocybin analog to enter clinical development -Patient recruitment will start soon -Pharmacokinetic & safety data readout expected in Q4 2022 Read more:

1

12

45

CybinInc

@CybinInc

7 months

“We are extremely grateful for this infusion of capital, which will enable us to continue advancing our next-generation psychedelic development programs,” said Cybin CEO @insidepharma . “We are especially encouraged by the level of interest and support from a high-quality

3

12

46

CybinInc

@CybinInc

11 months

Tomorrow, November 30, at 10 am ET, Cybin will host an R&D Briefing where we will release topline Phase 2 efficacy data for CYB003 in Major Depressive Disorder, followed by a panel discussion with key opinion leaders on data and study designs, the current treatment landscape in

3

11

46

CybinInc

@CybinInc

2 months

“Supported by #FDA #BTD , #CYB003 's positive four-month durability data, & the start of #CYB004 Phase 2, we're rapidly progressing to bring potentially paradigm-shifting treatment options to patients with #MDD and #GAD .” — #Cybin CEO @insidepharma

4

17

48

CybinInc

@CybinInc

1 year

Cybin's EMBARK Open Access has surpassed 3000 enrollees! Our online course offers free foundational training and education for healthcare professionals, researchers, and individuals interested in the emerging field of psychedelic facilitation. Sign up for free here:

2

9

45

CybinInc

@CybinInc

7 months

#BREAKING Wednesday, March 13, 2024 @ 8:30AM EST – Join @insidepharma and @dramirinamdar as they provide a program update on CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of MDD, including 4-month durability results from the

7

12

41

CybinInc

@CybinInc

22 days

On Sunday, September 29 at 5:50 pm EST, CEO @insidepharma will appear on @drdrew on @FoxBusiness to talk about the breakthrough innovations Cybin is leading to revolutionize the treatment of mental health. #MentalHealthInnovation #Biotechnology #Neuropsychiatry

2

14

46

CybinInc

@CybinInc

6 months

"Like so many others, my own family has been impacted by both #depression and #addiction — it is heartbreaking to see how devastating these conditions can be for both the sufferers and their families," said #Cybin CEO Doug Drysdale @insidepharma in a recent interview with

3

16

46

CybinInc

@CybinInc

1 year

Cybin has entered into an agreement to acquire @SmallPharma , creating an international clinical-stage leader in novel psychedelic therapeutics. 🤝 🔬 🌟🧠 📆 Learn more at a joint Cybin and Small Pharma conference call today, August 28 2023, at 11:30 a.m. ET:

1

13

44

CybinInc

@CybinInc

4 months

To date, Cybin has shared positive Phase 2 topline results for CYB003 in participants with Major Depressive Disorder #MDD , evaluating the efficacy and safety of CYB003 with two doses, at up to 4 months. Learn more: ↩️ #psychedelicresearch

2

13

46

CybinInc

@CybinInc

10 months

2024 will be pivotal for Cybin as our clinical programs reach new milestones in revolutionizing the treatment of mental health — giving patients and providers new hope for longer lasting and improved outcomes. Learn more about our plans for the year ahead:

1

13

45

CybinInc

@CybinInc

11 months

“Q4 of 2023 and 2024 will be pivotal for Cybin as we expect topline clinical data readouts from both our Phase 1/2a trial of CYB003 — our deuterated psilocybin analog — and from our Phase 1 trial of CYB004 and SPL028: our deuterated DMT programs," said Cybin CEO @insidepharma

11

10

41

CybinInc

@CybinInc

1 year

Cybin is pleased to announce the results of its Annual and Special Meeting, with the majority of shareholders voting in favor of Cybin’s acquisition of @SmallPharma Together with Small Pharma, Cybin will aim to transform the current treatment landscape for mental health

3

13

42

CybinInc

@CybinInc

1 year

Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics

Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in...

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin”, or the “Company”) and Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (“Small Pharma”) are pleased to

www.businesswire.com

1

12

43

CybinInc

@CybinInc

4 years

NetworkNewsAudio – Cybin Corp. Targeting Underserved Mental Illnesses with Drugs Derived from Psychedelics

0

4

40

CybinInc

@CybinInc

1 year

This #WorldMentalHealthDay , Cybinauts take stock of the scale of unmet global need and rededicate ourselves to the mission of revolutionizing mental health treatment for the benefit of patients everywhere. $CYBN #ChangingMinds #researchanddevelopment #cybin #psychedelicresearch

1

13

41

CybinInc

@CybinInc

9 months

Despite the global prevalence of #anxiety disorders, current treatment options remain limited, with suboptimal response and remission rates. We look forward to exploring the potential of #CYB004 #DMT to offer more effective, convenient, and patient-friendly treatment options.

4

9

39

CybinInc

@CybinInc

8 months

During the past three months, Cybin has made exciting progress with positive topline data from our CYB003 and DMT clinical trials,forming the foundation of our next set of value-creating milestones as we advance our key programs this year Learn more: $CYBN

5

12

42

CybinInc

@CybinInc

10 months

Embracing #MentalWellnessMonth with a focus on transformative care. At Cybin, we believe in the power of innovative therapies to reshape mental wellness. Join us in promoting a future where wellness is accessible to all. $CYBN #MentalWellness #CybinInnovation #ChangingMinds

0

6

39

CybinInc

@CybinInc

9 months

#WATCH Cybin CEO @insidepharma joins @DeepakChopra , @ChopraFNDN , @scottomelianuk , and Gabriella Wright to talk about how media shapes public awareness of psychedelics. Watch here: $CYBN #Cybin #MentalHealthInnovation #PsychedelicRevolution

6

12

41

CybinInc

@CybinInc

2 months

Clinical site selection is complete for #Cybin ’s Phase 3 multinational study of #CYB003 — our deuterated psilocybin analogue for the adjunctive treatment of Major Depressive Disorder #MDD — which is expected to begin soon. Learn more:

4

12

42

CybinInc

@CybinInc

11 months

Don't miss Cybin's R&D Briefing on Thursday, November 30 at 10am ET in New York City, where we will release topline Phase 2 efficacy data for CYB003 in Major Depressive Disorder, followed by a panel discussion with key opinion leaders on data and study designs, the current

5

12

39

CybinInc

@CybinInc

3 years

Cybin has recruited extra muscle to help navigate the regulatory process as it readies a clinical trial on its sublingual formulation of psilocybin, the psychedelic compound found in “magic mushrooms,” for patients with major depressive disorder. $CLXPF

3

11

37

CybinInc

@CybinInc

3 years

Happy New Year! As we look back on 2021, we’re so proud of how far our team has come. Cheers to all of the opportunity 2022 will bring. #HappyNewYear

1

9

38

CybinInc

@CybinInc

1 year

Cybin CEO Doug Drysdale ( @insidepharma ) discussed upcoming milestones and our FDA Breakthrough Therapy Designation application for CYB003 with AlphaNooner @AdvisorShares . 📺 Watch his full interview here: ↩️

0

12

39

CybinInc

@CybinInc

3 months

Learn more about #CYB004 : Cybin's Phase 2 proprietary deuterated dimethyltryptamine #DMT program for the treatment of Generalized Anxiety Disorder #GAD : ↩️ #MentalHealthInnovation #Biotechnology

4

17

40

CybinInc

@CybinInc

6 months

🌍 This #WorldHealthDay , we at #Cybin are committed to changing minds and revolutionizing mental healthcare for the benefit of patients everywhere. @WHO #Psychedelics #MentalHealthInnovation

2

8

41

CybinInc

@CybinInc

2 years

Cybin has received approval for First-in-Human dosing of CYB004, marking the first-ever trial to evaluate deuterated DMT in humans. Learn more: $CYBN #cybin #mentalhealth #clinicaltrials

3

5

37

CybinInc

@CybinInc

11 months

We'd like to congratulate Cybin advisors Alex Belser, PhD and Bill Brennan, authors of a new book from Oxford University Press, EMBARK Psychedelic Therapy for Depression: A New Approach for the Whole Person. The book provides a comprehensive guide to EMBARK, a leading edge model

2

5

39

CybinInc

@CybinInc

4 months

#Cybin 's #CYB003 received the first known U.S. #FDA Breakthrough Therapy Designation ( #BTD ) for an adjunctive psychedelic-based therapy for Major Depressive Disorder ( #MDD ) — validating its potential for significant clinical improvements over existing treatments and accelerating

1

10

40

CybinInc

@CybinInc

1 year

“This transaction creates a clear market leader in novel psychedelic therapeutics." — Cybin CEO Doug Drysdale @insidepharma ➡️ Learn more:

1

9

38

CybinInc

@CybinInc

11 months

Our CEO, @insidepharma , was at today’s @MilkenInstitute Future of Health Summit for a panel titled "Revolutionizing Mental Health Care Through Innovation" $CYBN #ChangingMinds #researchanddevelopment #cybin #psychedelicresearch #clinicalresearch #mentalhealthresearch #CybinInc

0

8

36

CybinInc

@CybinInc

1 year

Cybin's #Embark Open Access has surpassed 2000 enrollees! Covering topics such as safety, ethics, and practical application, our online course offers free foundational training and education for healthcare professionals, researchers, and individuals interested in the emerging

0

12

39

CybinInc

@CybinInc

11 months

📅 Save the Date: On November 30 at 10am ET, Cybin will host an R&D briefing in New York City featuring the release of Phase 2 topline safety and efficacy data for CYB003 in Major Depressive Disorder — led by members of Cybin’s leadership and scientific teams along with key

1

11

36

CybinInc

@CybinInc

4 years

Cybin x @KernelCo 's vision for the future of #mentalhealth "We hope to achieve several things with Cybin. The first improving the patient experience by improving the safety and efficacy of #psychedelic therapeutics..." - @bryan_johnson Read more:

0

9

37

CybinInc

@CybinInc

2 years

Interim findings from Cybin's ongoing Phase 1/2a clinical trial evaluating CYB003 demonstrated positive observations, including a rapid and short-acting psychedelic response in participants. $CYBN #researchanddevelopment #psychedelicresearch #clinicalresearch #mentalhealth

0

8

33

CybinInc

@CybinInc

7 months

The U.S. #FDA recently granted Breakthrough Therapy Designation #BTD to Cybin’s #CYB003 for the treatment of Major Depressive Disorder #MDD . BTD is designed to expedite the development and review of drugs intended to treat a serious condition where preliminary clinical evidence

2

9

36

CybinInc

@CybinInc

3 months

Learn more about #CYB004 : Cybin's Phase 2 proprietary deuterated dimethyltryptamine #DMT program for the treatment of Generalized Anxiety Disorder #GAD : ↩️ #MentalHealth #Biotechnology

4

14

36

CybinInc

@CybinInc

1 year

Cybin’s newly granted patent covers deuterated tryptamine analogues, adding to what will become the largest intellectual property portfolio in the psychedelic drug development sector — with 29 patents granted and over 150 patents pending — when Cybin's acquisition of @SmallPharma

1

12

34

CybinInc

@CybinInc

5 months

#Cybin CEO Doug Drysdale ( @insidepharma ) talked about the future of treating #depression at the 27th Annual Milken Institute Global Conference last week. 📺 #WATCH the full panel: ↩️ #MentalHealth #Psychedelics #Biotech

1

16

36

CybinInc

@CybinInc

1 year

When our acquisition of @SmallPharma closes, Cybin will have the industry’s largest, most advanced, and well-protected deuterated DMT program. Learn more: ↩ #DMT #psychedelicmedicine #mergersandacquisitions #ip

2

5

35

CybinInc

@CybinInc

7 months

Tomorrow, join CEO @insidepharma for a fireside chat at Public Ventures Discovery Day, a unique event for investors to learn about a curated group of venture-stage, deep-tech companies; share feedback and questions with company leaders; and connect with like-minded investors.

1

10

32

CybinInc

@CybinInc

9 months

With positive data from two Phase 1 studies of our proprietary deuterated #DMT molecules, CYB004 and SPL028, #Cybin is well-positioned to initiate a Phase 2a study of CYB004 in Generalized Anxiety Disorder this quarter. Learn more:

3

12

35